感染

订阅

MedSci主页 / 所有栏目 / 感染

2019年美国皮肤病学会（AAD）年会：Verrica制药公布了VP-102的全新临床试验结果

2019-03-04 不详 网络

VP-102皮肤病学软疣
关注

Verrica是一皮肤病学家医疗公司，致力于开发和商业化新型治疗方法，为皮肤病患者提供有意义的治疗手段，Verrica宣布将在2019年美国皮肤病学会（AAD）年会上公布两项III期临床试验结果，以证明候选化合物VP-102治疗传染性软疣患者的有效性和安全性。

Verrica是一皮肤病学家医疗公司，致力于开发和商业化新型治疗方法，为皮肤病患者提供有意义的治疗手段，Verrica宣布将在2019年美国皮肤病学会（AAD）年会上公布两项III期临床试验结果，以证明候选化合物VP-102治疗传染性软疣患者的有效性和安全性。结果显示，VP-102的两项试验都成功地达到了主要终点。在每项试验中，VP-102治疗的患者在12周内完全清除了所有软疣病变。

圣地亚哥Rady儿童医院儿科和青少年皮肤科主任医学博士Lawrence Eichenfield表示：“来自第III阶段的CAMP-1和CAMP-2试验的数据证明了VP-102具有治疗和根除软疣的潜力，这是一种高度传染性的病毒性皮肤感染，目前尚无FDA批准的治疗药物。目前的治疗方法有明显的局限性，包括疼痛、疤痕和未经验证的疗效，且许多不适合儿童使用。VP-102解决了这些严重皮肤病变的未满足的医疗需求”。


原始出处：

http://www.firstwordpharma.com/node/1627746#axzz5h9uGHFCc

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826120, encodeId=d44d182612003, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jun 28 08:09:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703592, encodeId=e23f1e0359292, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Sun Nov 10 19:09:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665357, encodeId=ebde166535e66, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Thu Nov 28 12:09:00 CST 2019, time=2019-11-28, status=1, ipAttribution=)]
    2019-06-28 一叶知秋

    #皮肤病#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1826120, encodeId=d44d182612003, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jun 28 08:09:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703592, encodeId=e23f1e0359292, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Sun Nov 10 19:09:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665357, encodeId=ebde166535e66, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Thu Nov 28 12:09:00 CST 2019, time=2019-11-28, status=1, ipAttribution=)]
    2019-11-10 surilei

    #ERR#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1826120, encodeId=d44d182612003, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jun 28 08:09:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703592, encodeId=e23f1e0359292, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Sun Nov 10 19:09:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665357, encodeId=ebde166535e66, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Thu Nov 28 12:09:00 CST 2019, time=2019-11-28, status=1, ipAttribution=)]
    2019-11-28 12498e8em80暂无昵称

    #VP-102#

    0